Health News Releases

  • Today May 23
December 10, 2013 10:00
Apira Science, Inc. Accelerates Global Growth Through Exclusive Distribution Partnership with China Central Pharmaceuticals
Apira Science, Inc. has named China Central Pharmaceuticals Ltd. its exclusive distributor of the iGrow® Hair Growth System in the Chinese market. The partnership highlights Apira’s growing success in
Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
December 10, 2013 09:17
Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced updated overall survival data from two ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinica
December 10, 2013 08:40
Updated Data with Oral Proteasome Inhibitor MLN9708 Reported in Newly Diagnosed Multiple Myeloma Patients
Takeda Pharmaceutical Company Limited (TSE:4502) today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalido
December 09, 2013 11:55
Celsis and CoValence Recognised for Transformative Supply Chain Project
The collaboration of Celsis International and CoValence Laboratories has been named the 2013 Supply & Demand Chain Executive (SDCE) Top 100 -“100 Great Supply Chain Projects” for delivering measurable
December 03, 2013 17:10
New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes
For Non-US and Non-UK Media Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with
December 02, 2013 17:29
Largest global survey investigating early Type 2 Diabetes conversations launched by Boehringer Ingelheim and Eli Lilly and Company in partnership with the International Diabetes Federation
Boehringer Ingelheim and Eli Lilly and Company today announced the launch of the largest multinational survey to investigate early conversations between physicians and people living with Type 2 Diabet
Gantry Treatment System
December 02, 2013 11:55
Sumitomo Proton Therapy System Clears FDA 510(k)
Sumitomo Heavy Industries, Ltd. (TOKYO:6302) announced today that it had received US FDA 510(k) clearance of its Proton Therapy System. It is the first 510(k) cleared medical device for Sumitomo.
KOHI successfully concluded Population and Reproductive Health for Pakistan Program with KOICA.
November 29, 2013 09:28
KOHI successfully concluded ‘Population and Reproductive Health for Pakistan’ Program With KOICA
Korea Human Resource Development Institute for Health and Welfare, KOHI (President; Ryu Hoyoung) successfully concluded ‘Population and Reproductive Health for Pakistan’ Program with KOICA. Delegates
November 28, 2013 14:20
Saudi Arabia Hosts International Forum on Brain Research and Personalized Healthcare
The Kingdom of Saudi Arabia will host a leading international forum, on brain research and personalized healthcare: The Brain Forum - Challenging the Future. The forum is the first-of-its-kind in
November 26, 2013 16:10
Hepatitis C: Boehringer Ingelheim's faldaprevir granted accelerated assessment from European Medicines Agency
For media outside of the U.S.A., UK and Canada only The application for European marketing authorisation of faldaprevir*, a potent second generation oral protease inhibitor, has been fully validat
November 26, 2013 09:00
CHMP Recommends Otsuka's Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of DeltybaTM (delamani
November 26, 2013 09:00
Pradaxa® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY®
For media outside of the US, the UK & Canada only Prevention of ischaemic stroke (a stroke caused by a blood clot)9 is the reason to treat patients with atrial fibrillation (AF) with an anticoagul
November 26, 2013 08:00
Cho Named President of Harlan Korea
Kwan Goo Edmond (Ed) Cho, an industry veteran with a broad depth of experience in life sciences and pharmaceuticals, has been selected as the president of Harlan Korea (http://www.harlan.com/). As
November 25, 2013 14:10
Quintiles Named Best CRO at SCRIP Awards, Quintiles Infosario Safety System Wins Best Technological Development
Quintiles has received Scrip Awards’ Best Contract Research Organization honors for the second year running, and Best Technological Development in Clinical Trials for Quintiles Infosario Safety System
AHF Letter to Ahn Ho-young, Ambassador of the Republic of Korea, asking Korea to contribute its fair
November 25, 2013 11:45
AHF: South Korea Shortchanges Global Fund
AIDS Healthcare Foundation (AHF), the largest global AIDS organization, today asked the Republic of Korea to increase its generosity in its pledging commitment to the Global Fund to Fight AIDS, TB, an
November 25, 2013 11:08
CHMP Determines Dimethyl Fumarate in TECFIDERA® to be a New Active Substance in the European Union
Today Biogen Idec (NASDAQ: BIIB) reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has determined that dimethyl fumarate in TECFIDERA quali
November 22, 2013 08:40
Vietnam Ministry of Health and Quintiles Collaborate to Advance Clinical Trial Excellence
The Vietnam Ministry of Health’s Administration of Science, Technology and Training (ASTT) has signed an agreement with Quintiles to enhance clinical research in this growing nation of 90 million peop
November 20, 2013 10:02
Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations
For media outside of the US, the UK & Canada only-- Boehringer Ingelheim has announced plans to initiate two large, global clinical trials of Pradaxa® (dabigatran etexilate) evaluating its efficacy an
MEDIANA Healthcare Business Department Director Ki Won Kim and Professor Hee Jung Kim (from left) du
November 20, 2013 09:43
MEDIANA donates AEDs and display equipment for guide to Yonsei University
Medical device company MEDIANA (Chairman Moon Jong Kil) donated two automated external defibrillators (AED) and two design input databases (DID) to Yonsei University at Future Hall at Yonsei Universit
November 19, 2013 21:00
Vancive Medical Technologies™, CareFusion Sign Agreement for Antimicrobial Dressing
Vancive Medical Technologies™ and CareFusion Corporation (NYSE:CFN) today announced an exclusive agreement in the United States, Canada and Mexico for the licensing and distribution of Vancive’s BeneH
November 19, 2013 18:02
New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years
For media outside of the US, the UK & Canada only--Results from a new combined analysis of the pivotal Phase III RE-LY® trial and its extension study RELY-ABLE® show that, in long-term treatment, the
Reversal of dabigatran-induced anticoagulation with antibody fragment (Fab), measured using Diluted
November 19, 2013 09:15
First human data show promise of Boehringer Ingelheim’s specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation
For media outside of the US, the UK & Canada only Presented for the first time at the American Heart Association’s (AHA) Scientific Sessions, results from the first clinical study in healthy volun
LUCAS 2 Chest Compression System
November 18, 2013 20:00
LINC Study Published in JAMA Reinforces the Safety and Effectiveness of the LUCAS Chest Compression System
AHA Scientific Sessions 2013 -- Physio-Control, the world leader in emergency medical response technologies, today announced that the comprehensive results of the LUCAS in Cardiac Arrest (LINC) clinic
November 18, 2013 15:00
Cisbio Bioassays, in Partnership with Argos Soditic, Makes a Major Step Forward in Its Development
The funds managed by Argos Soditic announce the acquisition, together with the management, of Cisbio Bioassays. This cutting-edge biotechnology company is the leader in the field of products and servi
November 18, 2013 09:15
Eurofins Lancaster Laboratories and Celsis International partner to provide pharmaceutical companies faster, more cost-effective rapid micro validation and screening services than traditional methods
Eurofins Lancaster Laboratories, the global leader in bio/pharmaceutical GMP product testing, and Celsis International Ltd., the global leader in rapid microbial detection systems, announced today tha
25 per page50 per page75 per page100 per page